Sapienza P, Tedesco M, Burchi C, Battistini M, Cavallaro A
I. Istituto do Clinica Chirurgica, Università degli Studi di Roma, La Sapienza.
Ann Ital Chir. 1995 Sep-Oct;66(5):651-63.
Adrenocortical carcinoma is a rare malignant tumor. The survival rate is related to a radical tumor resection. However, adrenocortical carcinomas are usually diagnosed in advanced stage. Although some cases of long-term regressions of metastases under op'-DDD (Mitotane) therapy have been sometimes reported the overall efficiency of mitotane in prolonging life remains controversial. Between May 1975 and January 1994, 9 patients were surgically treated for adrenocortical carcinoma at our institution. There were 6 females and 3 males, mean age 40.8 years (median 40 years). Five (55.6%) patients presented with abdominal pain, whereas 4 (44.4%) patients had symptoms of hormone secretion (cortisol). One patient was lost at follow-up. Overall survival rate was 16.8 +/- 5.9 months, the survival rates according to tumor stage were: stage I. 58 months (1 case), stage II. 6 and 16 (2 cases; mean 11 months), stage III. 7, 15.17 and 22 (4 cases, mean 15 months) and stage IV. 9 months (1 case). The progression of the disease is not controlled by the administration of op'-DDD and the best treatment is represented by surgery.
肾上腺皮质癌是一种罕见的恶性肿瘤。生存率与肿瘤根治性切除有关。然而，肾上腺皮质癌通常在晚期才被诊断出来。尽管有时会报告一些在米托坦（邻对滴滴滴）治疗下转移灶长期消退的病例，但米托坦在延长生命方面的总体疗效仍存在争议。1975年5月至1994年1月，我院对9例肾上腺皮质癌患者进行了手术治疗。其中女性6例，男性3例，平均年龄40.8岁（中位数40岁）。5例（55.6%）患者出现腹痛，4例（44.4%）患者有激素分泌症状（皮质醇）。1例患者失访。总生存率为16.8±5.9个月，根据肿瘤分期的生存率分别为：Ⅰ期58个月（1例），Ⅱ期6个月和16个月（2例；平均11个月），Ⅲ期7个月、15个月、17个月和22个月（4例，平均15个月），Ⅳ期9个月（1例）。疾病进展不受米托坦治疗的控制，最佳治疗方法是手术。
